Certolizumab pegol:类风湿关节炎的新选择

Future Prescriber Pub Date : 2009-12-24 DOI:10.1002/fps.57

Margaret HY Ma MBBS, BSc, MRCP, MSc, Ernest HS Choy MD FRCP

{"title":"Certolizumab pegol:类风湿关节炎的新选择","authors":"Margaret HY Ma MBBS, BSc, MRCP, MSc, Ernest HS Choy MD FRCP","doi":"10.1002/fps.57","DOIUrl":null,"url":null,"abstract":"<p>Rheumatoid arthritis (RA) presents a significant burden to healthcare in the UK. New biological therapies have advanced treatment but at a high cost to the NHS. Certolizumab pegol is a new TNF inhibitor, providing an additional treatment option for RA. In this article Dr Ma and Dr Choy consider the efficacy of certolizumab pegol, and where it may fit into the RA armoury. Copyright © 2009 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 4","pages":"15-20"},"PeriodicalIF":0.0000,"publicationDate":"2009-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.57","citationCount":"0","resultStr":"{\"title\":\"Certolizumab pegol: a new option for rheumatoid arthritis\",\"authors\":\"Margaret HY Ma MBBS, BSc, MRCP, MSc, Ernest HS Choy MD FRCP\",\"doi\":\"10.1002/fps.57\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Rheumatoid arthritis (RA) presents a significant burden to healthcare in the UK. New biological therapies have advanced treatment but at a high cost to the NHS. Certolizumab pegol is a new TNF inhibitor, providing an additional treatment option for RA. In this article Dr Ma and Dr Choy consider the efficacy of certolizumab pegol, and where it may fit into the RA armoury. Copyright © 2009 John Wiley & Sons, Ltd.</p>\",\"PeriodicalId\":100566,\"journal\":{\"name\":\"Future Prescriber\",\"volume\":\"10 4\",\"pages\":\"15-20\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-12-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/fps.57\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/fps.57\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.57","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Certolizumab pegol: a new option for rheumatoid arthritis

Rheumatoid arthritis (RA) presents a significant burden to healthcare in the UK. New biological therapies have advanced treatment but at a high cost to the NHS. Certolizumab pegol is a new TNF inhibitor, providing an additional treatment option for RA. In this article Dr Ma and Dr Choy consider the efficacy of certolizumab pegol, and where it may fit into the RA armoury. Copyright © 2009 John Wiley & Sons, Ltd.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future Prescriber

自引率

0.00%

发文量

期刊最新文献

Promising new drugs and drug targets for HIV treatment Treatment of rheumatoid arthritis: current and future Lurasidone: new development for the treatment of psychosis Sunovion: innovative medicines for areas of unmet clinical need Role and cost effectiveness of bariatric surgery in T2DM